1. Comparison of Soluble Decoy IgG Fusion Proteins of BAFF-R and BCMA as Antagonists for BAFF
- Author
-
Sarah A. Bixler, Christine Ambrose, Yen-Ming Hsu, Jeffrey Thompson, Adrian Whitty, Teresa G. Cachero, Eric S. Day, Christopher D. Benjamin, Mohammad Zafari, Fang Qian, Marc Pelletier, Susan L. Kalled, Leonid Gorelik, Kevin Gilbride, and Dahai Gong
- Subjects
Cell Separation ,Biochemistry ,Receptors, Tumor Necrosis Factor ,Arthritis, Rheumatoid ,Mice ,immune system diseases ,Cricetinae ,hemic and lymphatic diseases ,B-Cell Activating Factor ,Lupus Erythematosus, Systemic ,Decoy receptors ,skin and connective tissue diseases ,Receptor ,B-Lymphocytes ,Mice, Inbred BALB C ,Chemistry ,Valine ,Flow Cytometry ,Phenotype ,Asparagine ,Decoy ,Dimerization ,Protein Binding ,Proline ,Cell Survival ,Recombinant Fusion Proteins ,Enzyme-Linked Immunosorbent Assay ,CHO Cells ,stomatognathic system ,Leucine ,medicine ,Animals ,B-Cell Maturation Antigen ,B-cell activating factor ,BAFF receptor ,Molecular Biology ,Lupus erythematosus ,Dose-Response Relationship, Drug ,Tumor Necrosis Factor-alpha ,Cell Membrane ,Membrane Proteins ,Cell Biology ,medicine.disease ,Fusion protein ,Mice, Inbred C57BL ,stomatognathic diseases ,Immunoglobulin G ,Immunology ,Spleen ,B-Cell Activation Factor Receptor - Abstract
BAFF is considered a therapeutic target because dysregulated production of BAFF can induce systemic lupus erythematosus-like phenotype in mice, and elevated levels of BAFF are associated with disease severity in systemic lupus erythematosus and rheumatoid arthritis patients. Fc fusion decoy receptors, BCMA-Fc and BAFF-R-Fc, are therapeutic candidates for blocking BAFF. While studying their interactions with BAFF, we found that BAFF-R-Fc is more effective than BCMA-Fc for blocking BAFF binding to its receptors. We also found that a trimeric BAFF can bind more than one BAFF-R-Fc but only one BCMA-Fc. Moreover, we show that, in contrast to monovalent BAFF-R-Fc, monovalent BCMA does not form stable complexes with BAFF. Differences in their interaction with BAFF predict BAFF-R-Fc would be a better inhibitor. Indeed, we show BAFF-R-Fc is 10-fold more efficacious than BCMA-Fc for blocking BAFF-induced B cell proliferation in vitro and for blocking BAFF-mediated survival of mouse splenic B lymphocytes in vivo.
- Published
- 2003
- Full Text
- View/download PDF